- Stocks
- Pharma & Healthcare
- Panacea Biotec
Panacea Biotec share price
NSE: PANACEABIOPharma & HealthcareBiotechnology
Panacea Biotec at a glance
Panacea Biotec (NSE: PANACEABIO) closed at ₹335.85 on 22 Oct 2026, down 1.22% on the day. With a market capitalisation of ₹2,057 Cr, it ranks 1133rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
Its return on equity was −1.0% in FY25. Over the past year the share price has fallen 24.2%. Its 52-week range is ₹292.40 (30 Mar 2026) to ₹647.00 (9 Jun 2026); the last close is 48.1% below the high. Promoters held 72.48% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹2,057 CrRank 1133 on NSE
- Price to book
- 3.32×FY25
- ROE
- −1.0%FY25
- ROCE
- −4.3%FY25
- Debt to equity
- 0.02FY25
- Net profit margin
- −1.6%FY25
- Book value / share
- ₹132.76FY25
- 52-week high
- ₹647.009 Jun 2026
- 52-week low
- ₹292.4030 Mar 2026
- 1-year return
- −24.2%
- RSI (14-day)
- 35.9
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.22% | −7.4% | −10.7% | −27.3% | −24.2% |
Panacea Biotec financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹544 Cr | ₹625 Cr | ₹661 Cr | ₹460 Cr | ₹559 Cr | ₹559 Cr |
| Operating profit | −₹156 Cr | −₹144 Cr | −₹227 Cr | −₹90 Cr | −₹35 Cr | −₹44 Cr |
| Net profit | −₹195 Cr | −₹148 Cr | ₹1,078 Cr | −₹34 Cr | −₹2 Cr | −₹9 Cr |
| EPS (₹) | −₹32.00 | −₹24.00 | ₹176.00 | −₹5.00 | ₹0.00 | −₹1.00 |
| Cash from operations | −₹30 Cr | ₹107 Cr | −₹108 Cr | −₹422 Cr | −₹0 Cr | −₹27 Cr |
| Total debt | ₹610 Cr | ₹732 Cr | ₹30 Cr | ₹15 Cr | ₹15 Cr | ₹15 Cr |
| Shareholders' equity | ₹180 Cr | −₹247 Cr | ₹853 Cr | ₹827 Cr | ₹826 Cr | ₹820 Cr |
Panacea Biotec shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 72.48% | 72.48% | 72.48% | 72.48% | 72.48% | 72.48% |
| Foreign institutions | 1.16% | 0.78% | 1.06% | 1.36% | 1.60% | 2.31% |
| Domestic institutions | 1.49% | 1.52% | 1.81% | 1.85% | 1.97% | 2.25% |
| Non-institutions | 24.86% | 25.22% | 24.66% | 24.30% | 23.96% | 22.96% |
Panacea Biotec vs peers
The listed Pharma & Healthcare companies nearest to Panacea Biotec by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MEDIASSISTMedi Assist Healthcare Services | ₹291.75 | −0.61% | −46.7% | ₹2,179 Cr | 24.1 | — |
| SYNCOMFSyncom Formulations (India) | ₹22.83 | +3.21% | +38.8% | ₹2,146 Cr | 28.2 | — |
| INDOCOIndoco Remedies | ₹230.55 | +0.74% | −21.9% | ₹2,128 Cr | — | — |
| PANACEABIOPanacea Biotec | ₹335.85 | −1.22% | −24.2% | ₹2,057 Cr | — | — |
| SAKARSakar Healthcare | ₹923.90 | +2.66% | +156.4% | ₹2,056 Cr | 67.6 | — |
| SAIPARENTSai Parenterals | ₹461.90 | −1.31% | — | ₹2,041 Cr | 103.6 | — |
| BETABeta Drugs | ₹1,773.00 | +5.60% | +3.3% | ₹1,966 Cr | 43.4 | — |
Ask anything about Panacea Biotec
Pivot answers on the live chart with evidence you can check, and tests strategies against PANACEABIO's own history. Try: “Why has PANACEABIO moved over the last three months?” · “Backtest a 50-day moving-average crossover on PANACEABIO over five years” · “Compare PANACEABIO with MEDIASSIST on margins and valuation”
Frequently asked questions about Panacea Biotec
What is the share price of Panacea Biotec today?
Panacea Biotec (NSE: PANACEABIO) last closed at ₹335.85 on 22 Oct 2026. Its 52-week high is ₹647.00 and its 52-week low is ₹292.40.
What is the market cap of Panacea Biotec?
Panacea Biotec's market capitalisation is ₹2,057 Cr (₹2,057 Cr) at the 22 Oct 2026 close, ranking 1133rd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Panacea Biotec?
Return on equity was −1.0% in FY25 and return on capital employed was −4.3% in FY25 (consolidated figures).
Is Panacea Biotec a debt-free company?
Panacea Biotec is close to debt-free: its debt-to-equity ratio was 0.02 in FY25.
How has Panacea Biotec stock performed over the last year?
Panacea Biotec's share price has fallen 24.2% over the past year, −27.3% over three months and −10.7% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Panacea Biotec?
As of 30 Jun 2026: promoters 72.48%, foreign institutions 2.31%, domestic institutions 2.25%, non-institutions 22.96%.
Who are Panacea Biotec's competitors?
The listed Pharma & Healthcare companies closest to Panacea Biotec by market cap are Medi Assist Healthcare Services, Syncom Formulations (India), Indoco Remedies, Sakar Healthcare, Sai Parenterals and Beta Drugs.
Is Panacea Biotec a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Panacea Biotec's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PANACEABIO against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with P · all NSE stocks · this page as text